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Diagnosis
Figure 3:  This table displays renal biopsy findings consistent with the different 
classifications of lupus nephritis (Lager, 2011).
Systemic Lupus Erythematosus (SLE) can be described as a chronic, complex, autoimmune disorder (McCance & Huether, 2014). 
Disproportionately affecting women, and those of Afro-Cuban, Hispanic, Asian, and American Indian descent, SLE has a prevalence 
of 2.0 to 7.6 cases per 100,000 persons in the United States. Characterized by chaotic autoantibody production, complement 
alterations, and formation of immune complexes, SLE has the potential to generate devastating damage to multiple organ systems. 
Formed from the binding of autoantibodies and self-antigens, immune complexes often result in renal damage, a significant 
complication of the disease. Through careful analysis and synopsis of literature, the writer intends to provide the audience with 
pathophysiologic concepts defining lupus nephritis (LN). Within ten years of SLE diagnosis, between 50% and 60% of adults 
diagnosed will go on to develop LN (Richey, 2014). Of those with LN, upwards of 17% will go on to develop end stage renal disease 
(Bose, Silverman, & Bargman, 2014).  The devastating course of this condition prompted the writer’s choice of LN as a topic of 
interest for the purpose of this project, as she wished to gain valuable knowledge regarding the ailment and implications for
advanced nursing practice.
Definitive diagnosis and classification of LN is made by determining the extent of 
glomerular injury via renal biopsy, urine, and blood studies. The classification scheme 
used to stage and type the severity of LN is comprised of six classifications. The mildest 
form of renal involvement, class I minimal mesangial lupus nephritis, is rarely diagnosed 
as the urinalysis remains normal, showing minimal if any protein. Biopsy is not warranted 
at this stage as serum creatinine also remains normal. Class II mesangial proliferative 
lupus nephritis is characterized by microscopic hematuria or proteinuria without renal 
insufficiency. Subendothelial deposits or glomerular scarring noted on light microscopy, 
are hallmarks of class III focal lupus nephritis and class IV diffuse lupus nephritis. 
Hematuria and proteinuria, decreased glomerular filtration rate and hypertension are 
often seen with class III, while the class IV patient will exhibit hematuria, proteinuria, 
reduce glomerular filtration rate, hypertension and nephrotic syndrome. The 
differentiation between class III and class IV is made through the determination of the 
percentage of glomeruli affected. If involvement of glomeruli tops 50%, class IV LN is 
diagnosed, while less than 50% involvement is consistent with class III. Class V, lupus 
membranous nephropathy, is characterized by glomerular capillary wall thickening and 
subepithelial immune complex deposits on light and electron microscopy. Class V 
patients 
present with hypertension and microscopic hematuria without significant serum 
creatinine elevation. Class VI, advanced sclerosing lupus nephritis, is characterized by the 
sclerosis of at least 90% of glomeruli on biopsy. Glomerular sclerosis is indicative of 
previously injury. However, no active glomerulonephritis will be seen. Patients exhibit 
proteinuria without active urine sediment (Bomback & Appel, 2016). 
Clinical Manifestations
Many patients experience no symptoms at all. Typically, LN is suspected in SLE patients producing abnormal urinalysis results, 
possibly with an elevated serum creatinine level. Patients may demonstrate persistent proteinuria greater than 0.5 grams per day, 
random protein/creatinine ratios greater than 0.5 grams, and the production of urine with active sediment consisting of blood cells 
and/or casts greater than 5 without urinary tract infection. Serum creatinine, blood urea nitrogen, and antiDNA studies may be 
elevated, while glomerular filtration rates and C3 and C4 complement may be low (Hahn et al., 2012). Interestingly, IgE is also noted 
to be elevated with both active SLE and LN. A prominent player in type I hypersensitive reactions, IgE has historically been identified 
in autoimmune illness. Dema et al. (2014) ascertain elevated autoreactive IgE levels to be in significant relationship with active SLE 
and LN. 
The advanced practice nurse should suspect LN in SLE patients presenting with selected symptoms.  Hahn et al. (2012) identify these 
signs as:
• Periorbital edema
• Edema of the upper and lower extremities
• Changes in urine appearance
• Weight gain
Figure 1:  Bubbles within urine samples are flag for proteinuria.  
Retrieved from http://www.kidney-cares.org/nephrotic-syndrome-
symptoms-complications/220.html
In addition to the above physical symptoms, patients with active LN typically demonstrate signs of active SLE.  As described by Hahn 
et al. (2012), these symptoms include:
• Malar (Butterfly) rash
• Light sensitivity
• Fatigue
• Arthralgias and arthritis
• Fever
• Gastrointestinal upset
• Ulcerations of the mouth and nose
• Pleurisy
• Hair loss
• Raynaud’s Phenomenon Figure 2:  The malar rash associated with active SLE.  
Retrieved from www.healthsurgical.com
Understanding the pathophysiology of LN is paramount to early diagnosis and 
treatment. Following a diagnosis of LN associated end stage renal disease, patients 
and providers face a three-year mortality rate of roughly 27% (Gomez-Puerta et al, 
2015). Given the autoimmunity and inflammation which contribute to renal damage, 
induction and maintenance therapies aim to immunosuppress and reduce 
inflammation. Cyclophosphamide, mycofenolate mofetil, and prednisone are 
commonly used medications for both induction and maintenance. The objective of 
induction, or initiation of therapy, is to quickly halt renal inflammation related to 
immune complexes in order to allow for tissue healing (Pons-Estel et al., 2011). This is 
accomplished through the use of potent immunosuppressants and corticosteroids over 
a course of three to six months. Complete remission occurs in a small number of 
patients, with the majority of LN patients relapsing. The goal of maintenance therapy 
is to limit relapses through continued use of drugs, all the while minimizing the 
toxicity, metabolic dysfunction, and other complications associated with such 
medications. While the most advantageous length of maintenance therapy time 
remains ambiguous, 12 – 36 month long courses have been studied (Parikh & Rovin, 
2016).  
It is of note to recognize the disproportionate number of non-white women of lower 
socioeconomic status diagnosed with LN.  Furthermore, SLE related end stage renal 
disease is linked to lower socioeconomic status (B. Rovin, personal communication, 
July 12, 2016).  This highlights the importance of patient education and health literacy. 
Discussions regarding disease progression and renal replacement associated with both 
non-compliance and treatment failure should be apart of education once a LN 
diagnosis is suspected.  Additional considerations as identified by Rovin (personal 
communication,  July 12, 2016) include:
• Management of hyperlipidemia and hyperglycemia, with goal low density 
lipoprotein (LDL) < 100 and goal hemoglobin A1c < 6.5
• Administration of angiotensin converting enzyme (ACE) inhibitors, and 
angiotensin II receptor blockers (ARBs) for those with glomerular disease and 
proteinuria > 3 months
• Use of prophylactic antibiotics for pneumocystis pneumonia (PCP) prevention in 
the immunocompromised patient
• Prophylactic proton pump inhibitor administration for ulcer prevention in those 
receive long term corticosteroid therapy
• Provision of appropriate medication education, including side effects and risks 
associated with use of immunosuppressants and corticosteroids
• The importance of the LN patient avoiding nephrotoxic substances such as non-
steroidal anti-inflammatories and intravenous iodinated contrast dye
• Dietary modifications for renal protection, including the need to choose foods 
low in sodium, potassium, protein, and phosphorus 
• Screening for malignancy and infection related to immunosuppression 
Routine care of the SLE patient should be completed every three to six months, with  
urine studies completed at every office visit to assess for the presence of protein, 
blood cells, and casts.  Serologic work up should include complete blood cell count, 
comprehensive metabolic screening, complement, immunoglobulin, and antiDNA
antibody testing. Careful attention should be paid to the physical assessment as well. 
Aside from the obtainment of vital signs, visual inspection of the face and extremities 
for evidence of edema, and the skin for dermatologic signs of renal disease such as 
thickening and pigmentary alterations, thorough evaluation of respiratory status 
should also occur. Information gained from inquiries regarding urinary habits can be 
crucial for early diagnosis of LN. For patients with suspicion for LN, prompt renal 
biopsy should be completed to determine the extent of kidney involvement (Hahn, et 
al, 2012). If medication is indicated for LN, patients should be seen every two weeks  
for follow up. Anticipation of complications should guide the provider’s use of 
prophylactic medications and utilization of multi-disciplinary team members such as 
dieticians, endocrinologists, hepatologists and hematologists. 
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